The present review describes in detail the existent data regarding feedback loops between miRNAs and cytokines or growth factors in the psoriatic inflammation. We have chosen to describe the roles of miR-31, miR-21, miR-146a, miR-155, miR-197 and miR-99a in this process. This choice derives from the fact that among around 250 miRNAs being altered in the psoriatic lesion, the comprehensive functional role was described only in those detailed above. In addition, considering the molecular targets and the pathways, which may possibly be regulated by those miRNAs, it seems that they may be chosen as preferred targets for the therapy of psoriasis.
| INTRODUC TI ON
Psoriasis results from aberration in the crosstalk between activated immunocytes and keratinocytes (KC). [1, 2] Pathogenic T cells infiltrate the skin and trigger a hyper-proliferative response of KC. [3] Those changes are due to the altered expression of growth factors, cytokines and their receptors. [4] MicroRNAs (miRNAs) are small non-coding RNAs with important roles in post-transcriptional gene expression regulation.
Deregulation of miRNAs and their regulated targets expression has been implicated in the pathogenesis of psoriasis. [5, 6] We analysed the available data regarding the miRNAs which have been deregulated in psoriasis [7] [8] [9] [10] [11] and found 33 miRNAs with potential or confirmed targets (Table 1) . Among those miRNAs, we focused at a distinct subgroup of six miRNAs, which form variable feedback-forward loops patterns allowing them to serve as fine tuners of the fluxes in signalling pathways which play major roles in the psoriatic inflammation.
We assume that those loops are of distinct regulatory value and that they may serve as favourite therapeutic targets for psoriasis.
| S E ARCH ME THODS
We searched the related articles indexed in PubMed database using Title/Abstract words (["microRNAs in psoriasis" or "miRNAs in psoriasis"] and ["microRNA-21/31/99a/155/146a/197" or "miR-21/31/99a/155/146a/197"]and ["psoriasis" or "keratinocyte" or "epidermis" or "skin" or "chronic skin inflammation" or "cancer"])
from inception up to December 2017. All literature focusing on the mechanisms of miR-21, miR-31, miR-155, miR-146a, mir-99a and miR-197 in skin and in KCs was considered, without restriction for investigated subjects.
| MIR-21 , TG F-β AND TNF-α
MiR-21 is one of the most upregulated miRNAs in psoriasis. [7, 8, [11] [12] [13] It was suggested as a biomarker in the blood of psoriasis patients. [14] MiR-21 targets SMAD7 which acts as an antagonist of TGFβ1 signalling. [15, 16] TGF-β expression is increased in psoriatic serum and [8, 10, 91, 93, 94] miR-146a Upregulation Targeting TNF receptor-associated factor 6 (TRAF6) and IL-1 receptor-associated kinase 1 (IRAK1), thus the production and effect of cytokine IFN-γ, TNF-α, IL-6, IL-8 and IL-1. miR-146a is known as the negative regulation of the immune response [10, 86, 91, 95] miR-125b1 Downregulation Fibroblast growth factor receptor 2 (FGFR2) was identified as one of the direct targets for suppression by miR-125b [10, 93, 95, 96] miR-21 Upregulation CKAP2, E2F3, MSH2, CDK6, PDCD4, CDC25A. MSH2 protein levels were decreased upon miR-21 expression [10, 11, 13, 91, 95] miR-223 Upregulation MiR-223 is predicted to target GLUL (glutamate-ammonia ligase) and SMAD3 (SMAD family member 3). miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis [8, 91, 97] miR-31 Upregulation Serine/threonine kinase 40 (STK40), a negative regulator of NFκB signalling, is a direct target for miR-31 [8, 34, 91] miR-142-3p Upregulation MiR-142-3p displayed strong evidence of immune cell staining and considered to have a role in epidermal inflammation in psoriatic lesions [8, 11] miR-424 Downregulation Decreased expression of miR-424 causes increased keratinocyte proliferation seen in epidermis of psoriasis via MEK1 and cyclin E1 [7, 98] miR-33 Upregulation Post-transcriptional suppression of the cholesterol transporter ATP-binding cassette transporter A1 (ABCA1), leading to abnormal regulation of cholesterol efflux from macrophages [93, 99] miR-99a Downregulation MiR-99a contributes to the homoeostasis of IGF-1R expression. The elevation of IGF-1R in the psoriatic lesion drives the tissue towards proliferation and less differentiation. miR-99 family members regulate cell proliferation, cell migration and AKT/mTOR signalling [9, 69] miR-150 Downregulation MiR-150 regulates human keratinocytes' proliferation in hypoxic conditions through targeting HIF-1α and VEGFA in psoriasis [6, 100] miR-423 Downregulation miR-423 is downregulated in uninvolved skin as in the lesion skin in comparison with normal skin [9] miR-197 Downregulation MiR-197 targets IL22R1 and IL-17A subunits which are involved in psoriasis pathogenesis [9, 55, 62] miR-143 Upregulation MiR-143 targets directly Bcl-2 which in psoriasis vulgaris had lower expression than healthy subjects, perhaps due to cell proliferation of cortical cells and inflammatory stimulus in psoriasis vulgaris. miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis [97, 101] miR-221/222 Upregulation MiR-221 and miR-222 lead to degradation of TIMP3 resulting in decreased TIMP3 protein level, downregulation of TIMP-3, followed by an upregulation of TACE activity, resulting in dramatically increased soluble TNF-α levels [11, 102] miR-155 Upregulation MiR-155 significantly inhibits proliferation, migration and invasion and promotes apoptosis through PTEN signalling pathway in psoriasis cells. SOCS1 which is critical in limiting STAT-mediated signalling is one of miR-155 targets [11, 43, 103] miR-135b Upregulation IV collagen is a target of miR-135b, and inhibition of miR135b may improve the microenvironment and may increase the proliferative potential of basal cells [8, 104] miR-378 Upregulation MiR-378 is proposed to promote VEGF expression by competing with miR-125 (which was modestly downregulated in PP skin) for the same binding site in the VEGF 3′UTR [8, 105] miR-17 Upregulated Jak1 protein synthesis was acutely reduced by TCR-responsive microRNAs in the miR-17 family, which targeted Jak1 mRNA (messenger RNA) to inhibit its translation [8, 106] miR-200a Upregulated MiR-200a suppressed the proliferation of HCC cells by induction of G1 phase arrest. Furthermore, CDK6 was identified as a novel functional target of miR-200a [8, 107] miR-147b Upregulated MiR-147 induced by both NFκB and IRF3; meanwhile, it functions as inflammation modulator miRNA [8, 108] miR-10a Downregulated Oncogene HOXA1 is a direct target of miR-10a in megakaryocytopoiesis and human pancreatic cancer [8, 109] miR-100 Downregulated MiR-100 directly targeted the mTOR 3′UTR and repressed the expression of mTOR, a tumor-related gene [8, 69] miR-210 Upregulation Overexpression of miR-210 inhibits FOXP3 expression and impairs the immunosuppressive functions of Treg cells in CD4+ T cells [110] miR-19a Upregulation Regulatory microRNA of TNF-α [111] (Continues)
skin. [17] TGF-β expression correlates with skin inflammation and psoriatic phenotype. [18, 19] TGF-β1 and activation of TGF-β receptor initiate the transcription of miR-21 in epidermal KC in vitro and in vivo models. [15, 20] Thus, by preventing excessive SMAD7 protein expression, miR-21 maintains its own expression in a positive/positive feedback loop ( Figure 1A ).
An additional mechanism of positive/positive mode of enhancement of miR-21 is through the targeting of TIMP3 by miR-21 (Figure 1 B). TIMP3 was found to be a direct target of miR-21. [21] [22] [23] TIMP3 is a highly potent inhibitor of TNF-α-converting enzyme (TACE), also known as ADAM17. It cleaves the inactive form of TNF-α, to its soluble activated TNF-α configuration. [24] Soluble TNF-α, through binding to TNF-α receptor, activates STAT3. [25] STAT3 is a well-known transcriptional activator of miR-21. [26] [27] [28] [29] [30] [31] Interestingly, miR-21 inhibition is beneficial in the treatment of psoriasis.
[13]
| MIR-31 AND NFκ B PATHWAY
MiR-31 plays an important regulatory role in proliferation and differentiation of KC. [32] MiR-31 expression is upregulated in psoriatic blood and skin in comparison with normal blood and skin. [8, 10, 11] In the humanized mouse psoriasis model, miR-31 was the highest expressed miRNA. [33] It plays a role in regulating the production of inflammatory mediators and leucocyte chemotaxis to the skin, and hence, its inhibition may be a potential therapeutic option in psoriasis. [8, 10, 11, 32, 34] NFκB is a crucial mediator involved in the pathogenesis of psoriasis; it is involved in variety of immune and inflammatory pathways, in KC proliferation, differentiation and apoptosis. Increased NFκB activation is demonstrated in involved as compared with uninvolved psoriatic skin. [16, 35] Inflammatory cytokines IL-1, IL-6, IL-17A, TNF-α, IFN-γ and IL-22 increased miR-31 expression in primary KC. This enhancement was accompanied with activation of the signalling of NFκB and binding of the p65 component of NFκB to the putative binding site in the promoter element of miR-31. [33] Moreover, one of the targets of miR-31 is a serine/threonine kinase 40 (STK40), a negative modulator of NFκB signalling. [34] Thus, the increased expression of miR-31 enhances NFκB signalling, which increases its expression. MiR-31 maintains its expression and allows the stable activation of NFκB through a positive/positive feedback loop (Figure 2 ).
| MIR-155, TNF-α AND IFN -γ
MiR-155 expression is enhanced by NFκB and its promoter has three NFκB binding sites. [36] MiR-155 is upregulated in psoriatic lesions. [7, 8, 11, 37] MiR-155 may promote differentiation towards a Th1 phenotype by limiting the expression of IL-4, a cytokine whose expression characterizes the Th2 phenotype. Hence, upon T-cell activation, miR-155 expression increases and may possibly control the differentiation of CD4+ T cells into several T-cell subsets in chronic skin inflammation. [38] MiR-155 is induced by TNF-α and IFN-γ, in primary KC cultures. This induction may be mediated via NFκB. [39] [40] [41] MiR-155 serves as a pro-inflammatory miRNA, as it leads to the miRNA Expression in psoriatic skin Mediated effect miR-369-3p Upregulation MiR-369-3p levels in skin had a positive linear relationship with psoriasis activity severe index (PASI) scores [112] miR-1266 Upregulation Serum miR-1266 levels were considerably higher in psoriasis patients than in healthy control subjects [113] miR-4516 Upregulation Overexpression of hsa-miR-4516 downregulates STAT3 (directly targets STAT3 protein by binding to its 3′UTR), p-STAT3, CDK6 and UBE2N proteins that are consistently upregulated in psoriasis and induces apoptosis [114] miR-22 Upregulation MiR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1 [11, 115] miR-326 Downregulation MiR-326 plays a key role in regulating TGF-β1 expression and other profibrotic genes and could be useful in developing better therapeutic strategies for alleviating lung fibrosis [9, 116] miR-498 Upregulation MiR-498 is downregulated in involved and non-involved psoriatic skin compared with healthy skin, pointing to a central role of this miRNA in the skin of patients diagnosed with psoriasis [11] miR-24-1 Upregulation MiR-24 as a miRNA that targets Net1A during TGF-b-induced EMT [11, 117] F I G U R E 1 MiR-21 regulation in a positive/positive (+/+) manner. A, Following TGF-β binding to its receptor, a downstream signalling is activated causing transcription of miR-21; meanwhile, miR-21 itself targets directly SMAD-7 mRNA, which inhibits TGF-βR and sends it to degradation. B, MiR-21 inhibits TIMP-3 expression thus leading to overexpression of TNF-α via the activation of TACE/ ADAM17. As a result, TNF-α R downstream signalling activates STAT3 signalling and enhances miR-21 expression
production of TNF-α. [42] SOCS1 [member of suppressor of cytokine signalling family] is among miR-155 targets. [39, 43, 44] SOCS proteins are critical in limiting STAT-mediated signalling, activated through cytokine receptors. [44] SOCS1 is rapidly upregulated upon signalling through type I and II cytokine receptors, mainly by IFN-γ. [44] It is a general regulator of cell signalling downstream to several cytokines: IL-2, IL-4, IL-6, IFN-γ, along with growth factors like growth hormone, and erythropoietin. [45] Gene-wide meta-analyses have shown that SOCS1 is an independent predisposing locus for psoriasis in European populations. [46] An additional target of miR-155 is PTEN. [47] Through targeting PTEN, which inhibits PI3K to AKT signalling, miR-155 enhances its own effect and creates a positive feedback loop regulation. [48, 49] Taken together, we can see a positive/positive mode of feedback loop, in which pro-inflammatory cytokines like TNF-α and IFN-γ increase miR-155, while miR-155 targets SOCS1 and PTEN, [37] which are negative regulators of cytokine signalling. In this way, miR-155 contributes to inflammation maintenance in psoriasis ( Figure 3 ).
| MIR-14 6A AND NFκ B PAT H WAY
Exposure to LPS leads to rapid induction of miR-146a in human monocytic THP-1 cells. [50] This work also found that miR-146a is a NFκB-dependent gene, and its promoter has two binding sites for NFκB. [50] It plays an important role in the suppression of innate immune responses in KC during chronic skin inflammation. [51, 52] MiR146a was shown to target both IRAK1 and TRAF6, two proteins in the signalling to active NFκB. [50] In addition, miR-146a targets CARD10, a G protein-coupled receptor, an additional signalling activator of NFκB. [53] Taken together, miR-146a expression in KC is subjected to positive/negative feedback loop effect; miR-146a expression is enhanced by NFκB, while it targets several enhancers of the NFkB pathway ( Figure 4) . However, inherited deficiency of miR146a leads to earlier onset and exacerbation of skin inflammation, increased expression of IL-17, induced KC-derived inflammatory mediators, epidermal hyper proliferation and increased neutrophil infiltration. [10, 54] In psoriasis, miR-146a is overexpressed in lesions in comparison with uninvolved psoriatic skin. [8, 10, 11] However, its moderate overexpression in psoriasis does not result in decreased signalling to NFκB.
| MIR-19AND IL-22R A1/IL-17R A

MiR-197 expression is downregulated in psoriatic lesions in com-
parison with healthy skin. [9, 10] It was found that miR-197 decreases proliferation and migration and drives towards KC differentiation. [55] IL22RA1 subunit of IL-22 receptor is a validated target of miR-197 in KC. [55] IL22RA1 subunit is overexpressed in psoriasis. [56] [57] [58] [59] [60] [61] IL-22RA1
inhibition by miR-197 could partially explain the hyper proliferation and de-differentiated markers of psoriatic lesions. It was found also that miR-197 is activated by IL-22 binding to its receptor in KC via STAT3 pathway. [55] An another validated target of miR-197 in KC is IL17RA subunit of IL-17 receptor. [62] IL-17A, IL17RA ligand, is one of 
| MIR-99A AND I G F-1R
There are 3 members of the miR-99 family in humans (miR-99a, miR-99b and miR-100) located on distinct chromosomal regions. MiR-99 family members play an important role in regulating proliferation and migration of skin and oral mucosa epithelial cells. [69, 70] IGF-1R is a target of miR-99a. Transgenic mice overexpressing IGF-1 in the basal layer of skin epidermis exhibit epidermal hyperplasia, hyperkeratosis and squamous papillomas while IGF-1R knockout mice demonstrate severe hypoplasia. [71] [72] [73] [74] IGF-1R is known to be involved in the pathogenesis of psoriasis; it was shown to be upregulated in psoriasis, specifically in the proliferating basal layer of psoriatic lesions. [75] [76] [77] MiR-99a directly targets the IGF-1R mRNA 3′UTR and decreases IGF-1R protein levels. As the result, miR-99a drives the cells to slower proliferation and induces them towards differentiation. [9] In addition, miR-99 family miRNAs can target additional two proteins in the IGF-1 signalling pathway: Akt and mTOR. [78] Interestingly, in primary KC, treatment with IGF-1 increased the expression of miR-99a, suggesting that IGF-1R signalling upregulates the expression of miR99a which inhibits the IGF-1 signalling at three different proteins ( Figure 6 ). In psoriatic biopsies, the expression of miR-99a and its family members was decreased in comparison with healthy skin. [7] [8] [9] [10] Moreover, it was found that miR-99a is mostly expressed in the upper part of the epidermis while IGF-1R was detected mainly in the basal layer of the epidermis [9] possibly due to the interaction between miR-99a and IGF-1R in a positive/negative manner ( Figure 6 ).
| SUMMARY AND CON CLUS I ON S
Psoriasis is driven by the interactions between epidermal KC and immunocytes. Within this interaction, multiple secreted cytokines and growth factors activate pathways which result in the typical pathologic features of the psoriatic lesion: marked hyper proliferation of KC along with de-differentiated epidermal layer. [79] Targeting cytokines or their receptors to inhibit the cytokine storm in psoriasis has proved its therapeutic efficacy. [80] [81] [82] However, it is still needed to expand our understanding of how to control this incurable, devastating process.
Several studies showed aberrant expression profiles of miRNAs in psoriasis in comparison with normal skin; about 250 miRNAs are found to be differentially expressed in psoriatic skin. [83] From those aberrant miRNAs, we reviewed in detail 6 miRNAs which are well characterized and involved in regulatory circuits with immune modulators and growth factors which participate in the pathogenesis of psoriasis.
MiRNAs act as silencers of their targets; however, they do not completely abolish the expression of a specific gene. They are involved in gene regulation networks, in which they act with other regulatory molecules, to affect signalling pathways at multiple levels.
[ 84] They operate as rheostats to fine-tune the protein level expression. [85] Reviews describe two opposite feedback loops: (i) positive-positive, does not fit to the detailed paradigm; miR-146a overexpression is expected to decrease the signalling through the NFκB pathway in psoriasis but in fact it is high. Even the expression of the direct target of miR-146a, IRAK1, is higher in the psoriasis lesion. [86] Thus, it seems that the role of miR-146a in the psoriatic inflammation is more complex. On the one hand, it was shown, in mouse model of psoriasis, that miR-146a knockout leads to earlier disease onset and more severe skin inflammation. [54] On the other hand, miR-146a is overexpressed in psoriatic lesions. Moreover, it was shown that polymorphism of miR-146a precursor (change of G to C), resulting in overexpression of miR-146a, [87] has a protective effect regarding psoriasis onset [54] Taken together, it seems that the effect of miR-146a in the psoriatic inflammation is not simply through the feedback loop we suggested. First, beside miR-146a, miR-146b also has modulating role in skin inflammation and proliferation. [88] Second, it was shown recently that miR-146a is involved in the EFG signalling through directly targeting FERMT1 [88] which regulates cell proliferation through the EGF signalling. [89] Obviously, looking at each miRNA as a solitary component in the network is simplifying the situation. Just from the six miRNAs we discuss, we can see that the same growth factor / cytokine can affect the expression of several miRNAs. TNF-α can affect the ex- but not in the psoriatic lesion? There is no evidence that miRNAs, which are aberrantly expressed in psoriasis, are located in psoriasis susceptibility genome regions. [90, 91] Only one polymorphism in the 3′UTR of BASIGIN (BSG) gene that is associated with psoriasis risk was shown to affect the binding of miR-492. [92] Are those aberrant expression patterns related to exposure of the lesion to immunocytes or because of genetic aberrations of the psoriatic skin? Part of the answer to this question could be obtained by comparing the expression of these miRNAs in the uninvolved skin of psoriasis patients to healthy skin. MiR-31 expression in uninvolved psoriatic skin is increased by threefold compared to healthy skin, without significant change in the expression of miR-21, miR-146a or miR-155. [8] In addition, there is a decrease of 10% and 35% in the expression in miR-197 and miR-99a, respectively, in the uninvolved psoriatic skin compared to healthy skin. [8] Similarly, the expression of miR-197 and miR-99a in uninvolved psoriatic skin is lower than in healthy skin. [9] As we wrote above, miRNAs are fine tuners; therefore, even small changes in the miRNAs expression might move the biochemical equilibrium to a new balance. It seems that in psoriatic skin, even in uninvolved regions, when miR-99a and miR-197 expression is already low, and miR-31 expression is already high, the biochemical equilibrium of the system is in a pro-inflammatory balance. This supports the hypothesis that abnormal expression of miRNAs may be central part of the pathogenesis of psoriasis. 
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